Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 23, 2017
What is the competitive landscape for TAKEDA PHARMS USA, and when can generic versions of TAKEDA PHARMS USA drugs launch?
TAKEDA PHARMS USA has seventeen approved drugs.| International Patents: | 1068 |
| US Patents: | 82 |
| Tradenames: | 17 |
| Ingredients: | 14 |
| NDAs: | 17 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
alogliptin and metformin hydrochloride | Tablets | 12.5 mg/500 mg and 12.5 mg/1000 mg | KAZANO | 1/25/2017 |
alogliptin | Tablets | 6.25 mg, 12.5 mg and 25 mg | NESINA | 1/25/2017 |
febuxostat | Tablets | 40 mg and 80 mg | ULORIC | 2/13/2013 |
colchicine | Tablets | 0.6 mg | COLCRYS | 12/23/2011 |
pioglitazone hydrochloride and metformin hydrochloride | Extended-release Tablets | 15 mg/1000 mg and 30 mg/1000 mg | ACTOPLUS MET XR | 9/23/2011 |
dexlansoprazole | Delayed-release Capsule | 30 mg | DEXILANT | 11/30/2010 |
dexlansoprazole | Capsule | 60 mg | DEXILANT | 8/25/2010 |
pioglitazone hydrochloride and glimepiride | Tablets | 30 mg/2 mg and 30 mg/4 mg | DUETACT | 12/22/2009 |
ramelteon | Tablets | 8 mg | ROZEREM | 7/22/2009 |
pioglitazone hydrochloride and metformin hydrochloride | Tablets | 15 mg/500 mg and 15 mg/850 mg | ACTOPLUS MET | 3/6/2008 |
lansoprazole | Delayed-release Orally Disinte | 15 mg and 30 mg | PREVACID | 12/27/2006 |
lansoprazole | Delayed-release Pellets/Capsul | 15 mg and 30 mg | PREVACID | 12/5/2005 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,211,205 | Pharmaceutical composition | ► Subscribe | |||||||||||||
| 8,729,030 | Peptides that bind to the erythropoietin receptor | ► Subscribe | |||||||||||||
| 7,683,053 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | ► Subscribe | |||||||||||||
| 9,125,910 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment | ► Subscribe | |||||||||||||
| 8,309,125 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | ► Subscribe | |||||||||||||
| 6,599,923 | Pharmaceutical composition | ► Subscribe | |||||||||||||
| 8,592,365 | Spacer moiety for poly(ethylene glycol) modified peptide based compounds | ► Subscribe | |||||||||||||
| 8,664,225 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition | ► Subscribe | |||||||||||||
| 7,795,428 | Dipeptidyl peptidase inhibitors | ► Subscribe | |||||||||||||
| 6,274,605 | Pharmaceutical composition | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Singapore | 160224 | ► Subscribe | |||||||||||||
| Slovenia | EP1956015 | ► Subscribe | |||||||||||||
| Japan | 5881962 | ► Subscribe | |||||||||||||
| Denmark | 0885210 | ► Subscribe | |||||||||||||
| World Intellectual Property Organization (WIPO) | 2007144005 | ► Subscribe | |||||||||||||
| Japan | 2013173763 | ► Subscribe | |||||||||||||
| Eurasian Patent Organization | 013427 | ► Subscribe | |||||||||||||
| Eurasian Patent Organization | 200970018 | ► Subscribe | |||||||||||||
| Australia | 2493599 | ► Subscribe | |||||||||||||
| Japan | 2005263780 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 00569 | Netherlands | ► Subscribe | PRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN COMBINATIE MET METFORMINEHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/12/780/001-028 20120720 | ||||||||||||
| C015/2010 | Ireland | ► Subscribe | SPC015/2010: 20101001, EXPIRES: 20230420 | ||||||||||||
| 1084705/05 | Switzerland | ► Subscribe | PRODUCT NAME: ALOGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 62955 21.11.2013 | ||||||||||||
| /2010 | Austria | ► Subscribe | PRODUCT NAME: FEBUXOSTAT IN DER KRISTALLFORM A; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421 | ||||||||||||
| 0861666/01 | Switzerland | ► Subscribe | FORMER REPRESENTATIVE: BOHEST AG, CH | ||||||||||||
| 1129088/01 | Switzerland | ► Subscribe | PRODUCT NAME: DEXLANSOPARAZOL; REGISTRATION NO/DATE: SWISSMEDIC 62993 09.05.2014 | ||||||||||||
| 2014044 | Lithuania | ► Subscribe | PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001-011 20110824 | ||||||||||||
| C 038/2006 | Ireland | ► Subscribe | SPC 038/2006: 20070528, EXPIRES: 20210619 | ||||||||||||
| 2014013,C1436271 | Lithuania | ► Subscribe | PRODUCT NAME: VORTIOKSETINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA RUGSTIES PRISIJUNGIMO DRUSKA; REGISTRATION NO/DATE: EU/1/13/891 20131218 | ||||||||||||
| C0008 | France | ► Subscribe | PRODUCT NAME: VILDAGLIPTINE OU UN DE SES SELS PHARMACETIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/07/414/001 DU 20070926; REGISTRATION NO/DATE AT EEC: EU/1/07/414/001-017 DU 20070926 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 23,001 others who get our Drug Patent Expiration Alerts:
